We performed an additional analysis to see whether patients receiving guideline-based HF medication (e.g., spironolactone, angiotensin-converting enzyme inhibitor, angiotensin II receptor blockers, or β-blocker) prior to admission would have difference in the prevalence of HF-related physical findings compared to those not receiving guideline-based treatment. The gene discussed is ACE; the disease is hydrops fetalis.